The 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer (one of the eight NCCN Guidelines originally published in 1996), has been published by the National Comprehensive Cancer Network (NCCN).
“We have made an incredible amount of progress in the diagnosis and treatment of prostate cancer since the NCCN Guidelines were published in 1996,” James L. Mohler, MD, Associate Director for Translational Research, Chair, Department of Urology, and Professor of Oncology, Roswell Park Cancer Institute and NCCN Guidelines Panel Chair for Prostate Cancer, said in a press release. “The death rate for men with prostate cancer has fallen from approximately 40,000 to 29,000[i], and the evolution of the NCCN Guidelines for Prostate Cancer has contributed significantly to that trend.”
Dr. Mohler further noted that for men diagnosed with prostate cancer, life expectancy has changed significantly.
These new NCCN Guidelines recommendations for early detection and care take into consideration life expectancy, which can be predicted from specific tables and fine-tuned depending on the patients’ comorbidities, among other different elements.
“The sole recommendation of active surveillance for men with NCCN Releases New Clinical Practice Guidelines in Oncology for Prostate Cancer
The 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer (one of the eight NCCN Guidelines originally published in 1996), has been published by the National Comprehensive Cancer Network (NCCN).
“We have made an incredible amount of progress in the diagnosis and treatment of prostate cancer since the NCCN Guidelines were published in 1996,” James L. Mohler, MD, Associate Director for Translational Research, Chair, Department of Urology, and Professor of Oncology, Roswell Park Cancer Institute and NCCN Guidelines Panel Chair for Prostate Cancer, said in a press release. “The death rate for men with prostate cancer has fallen from approximately 40,000 to 29,000[i], and the evolution of the NCCN Guidelines for Prostate Cancer has contributed significantly to that trend.”
Dr. Mohler further noted that for men diagnosed with prostate cancer, life expectancy has changed significantly.
These new NCCN Guidelines recommendations for early detection and care take into consideration life expectancy, which can be predicted from specific tables and fine-tuned depending on the patients’ comorbidities, among other different elements.
“The sole recommendation of active surveillance for men with